A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

Kastrati, Adnan; Mehilli, Julinda; Schühlen, Helmut; Dirschinger, Josef; Dotzer, Franz; M. ten Berg, Jurriën; Neumann, Franz‐Josef; Bollwein, Hildegard; Volmer, Christian; Gawaz, Meinrad; B. Berger, Peter; Schömig, Albert

doi:10.1056/nejmoa031859

Public

A Clinical Trial of Abciximab in Elective Percutaneous Coronary Intervention after Pretreatment with Clopidogrel

Published in New England Journal of Medicine • Jan 14, 2004

Authors:

Adnan Kastrati

Julinda Mehilli

Helmut Schühlen

Abstract

BACKGROUND: Whether the glycoprotein IIb/IIIa inhibitor abciximab is beneficial in patients undergoing elective percutaneous coronary intervention after pretreatment with clopidogrel is unknown. METHODS: We enrolled 2159 patients with coronary artery disease who underwent a percutaneous coronary int...

Subject

Abciximab

Medicine

Percutaneous coronary intervention

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!